Imunon (NASDAQ:IMNN) Price Target Cut to $12.00 by Analysts at HC Wainwright

Imunon (NASDAQ:IMNN) had its target price trimmed by HC Wainwright from $14.00 to $12.00 in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, EF Hutton Acquisition Co. I raised Imunon to a “strong-buy” rating in a research report on Monday, September 23rd.

Imunon Stock Down 3.7 %

Shares of NASDAQ IMNN opened at $0.75 on Monday. The stock has a market cap of $44.84 million, a PE ratio of -0.40 and a beta of 2.14. Imunon has a 52-week low of $0.48 and a 52-week high of $3.65. The business has a 50-day moving average price of $1.00 and a 200 day moving average price of $1.19.

Imunon (NASDAQ:IMNN) last announced its earnings results on Wednesday, August 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.04. Sell-side analysts anticipate that Imunon will post -1.68 earnings per share for the current year.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.